دورية أكاديمية
Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
| العنوان: | Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. |
|---|---|
| المؤلفون: | Basoli A; Department of Surgery, Università degli Studi La Sapienza, Policlinico Umberto I., Rome, Italy., Meli EZ, Mazzocchi P, Speranza V |
| المصدر: | Scandinavian journal of infectious diseases [Scand J Infect Dis] 1997; Vol. 29 (5), pp. 503-8. |
| نوع المنشور: | Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 0215333 Publication Model: Print Cited Medium: Print ISSN: 0036-5548 (Print) Linking ISSN: 00365548 NLM ISO Abbreviation: Scand J Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2007-2014 : London : Informa Healthcare Original Publication: Stockholm, Society for the Publication of Acta medica Scandinavica. |
| مواضيع طبية MeSH: | Abdomen*, Anti-Bacterial Agents/*therapeutic use , Bacterial Infections/*drug therapy , Cilastatin/*therapeutic use , Imipenem/*therapeutic use , Protease Inhibitors/*therapeutic use , Thienamycins/*therapeutic use, APACHE ; Adult ; Aged ; Anti-Bacterial Agents/administration & dosage ; Cilastatin/administration & dosage ; Female ; Humans ; Imipenem/administration & dosage ; Infusions, Intravenous ; Male ; Meropenem ; Middle Aged ; Prospective Studies ; Protease Inhibitors/administration & dosage ; Thienamycins/administration & dosage ; Treatment Outcome |
| مستخلص: | An open-label prospective, randomized, parallel multicentre study was undertaken to compare the efficacy and tolerability of 1.5 g/day intravenous imipenem/cilastatin with 3 g/day intravenous meropenem in the treatment of intra-abdominal infections. A total of 287 patients were enrolled: 201 patients, divided between the 2 treatment groups, were evaluable. Clinical outcome, bacteriological outcome, untoward microbiological effects, and clinical and laboratory adverse experiences were evaluated. 98% of patients receiving imipenem/cilastatin therapy were cured, with 96% showing eradication of infection. 95% of those on meropenem were cured, with 98% showing eradication. These differences in clinical and bacteriological outcome between the 2 treatments were not statistically significant. Two patients receiving imipenem/cilastatin and 5 receiving meropenem had untoward microbiological effects. There was a 0.7% frequency (1/139 patients) of possibly or probably drug-related clinical or laboratory adverse experiences with imipenem/cilastatin and a 2.7% frequency (4/148) with meropenem. The mean time to defervescence was significantly less for patients in the imipenem/cilastatin treatment group than for those receiving meropenem. This study shows that 1.5 g/day of imipenem/cilastatin is equivalent to 3.0 g/day meropenem in clinical and bacteriological outcome, as well as in incidence of side effects. |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Protease Inhibitors) 0 (Thienamycins) 141A6AMN38 (Cilastatin) 71OTZ9ZE0A (Imipenem) FV9J3JU8B1 (Meropenem) |
| تواريخ الأحداث: | Date Created: 19970101 Date Completed: 19980203 Latest Revision: 20181201 |
| رمز التحديث: | 20240627 |
| DOI: | 10.3109/00365549709011863 |
| PMID: | 9435041 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 0036-5548 |
|---|---|
| DOI: | 10.3109/00365549709011863 |